| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/24/2004 | US20040120956 CNGH0004 polypeptides, antibodies, compositions, methods and uses |
| 06/24/2004 | US20040120954 expression of PEX without a catalytic site of MT1-MMP on a cell surface directly prevents an association of two enzymes and inhibits the activation of proMMP-2 in a dose-dependent manner |
| 06/24/2004 | US20040120952 Anti-TNF antibodies and peptides of human tumor necrosis factor |
| 06/24/2004 | US20040120951 Human-type anti-blood coagulation factor viii antibody |
| 06/24/2004 | US20040120946 capable of efficient and selective adsorption of an antibody against beta 1-adrenoceptor and/or an antibody against M2 muscarinic receptor occurring in a body fluid (e.g. blood, plasma or the like) without requiring a pretreatment |
| 06/24/2004 | US20040120945 Cell surface molecule mediating cell adhesion and signal transmission |
| 06/24/2004 | US20040120943 Antithrombotic thrombin variants |
| 06/24/2004 | US20040120942 preparation of thrombin serum from the blood of a single human donor |
| 06/24/2004 | US20040120941 Administering oxalate-degrading microbes and oxalate-degrading enzymes to treat urolithiasis or kidney stones |
| 06/24/2004 | US20040120940 Placental alkaline phosphatase to control diabetes |
| 06/24/2004 | US20040120939 Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use |
| 06/24/2004 | US20040120938 Ingestible compositions comprising antibacterial agents |
| 06/24/2004 | US20040120934 Cloned ungulate embryos and animals, use of cells tissues and organs thereof for transplantation therapies including parkinson's disease |
| 06/24/2004 | US20040120930 Administering mutant epithelial nitric oxide synthase with mutation at a position corresponding to an amino acid residue in a mammalian eNOS that is phosphorylated in mammalian cells; |
| 06/24/2004 | US20040120928 Composite oncolytic herpes virus vectors |
| 06/24/2004 | US20040120926 Reactive oxygen metabolite inhibitors for use in compositions and methods of treatment |
| 06/24/2004 | US20040120925 Administering substance capable of inducing and proliferating dendritic cells or inducing gene expression of nerve growth factors; brain or nervous system disorders |
| 06/24/2004 | US20040120923 Method of treatment using a cytokine able to bind IL-18BP to inhibit the activity of a second cytokine |
| 06/24/2004 | US20040120917 Cosmetic or dermopharmaceutical composition comprising an enzyme which is insoluble in an aqueous medium, as well as its uses |
| 06/24/2004 | US20040120910 Methods for producing, films comprising, and methods for using heterogeneous crosslinked protein networks |
| 06/24/2004 | US20040120900 Intraoral calculus dissolving gel composition |
| 06/24/2004 | US20040120899 Methods of treating allergy by administering interleukin-17 receptor |
| 06/24/2004 | US20040120898 Methods of treating asthma by administering interleukin-17 receptor |
| 06/24/2004 | US20040120897 Method for administering insulinotropic peptides |
| 06/24/2004 | US20040120896 Buccal aerosol sprays or capsules using polar and non-polar solvent which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect |
| 06/24/2004 | US20040120895 Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| 06/24/2004 | CA2547899A1 Cell-based therapies for ischemia |
| 06/24/2004 | CA2511775A1 Hla-a1,-a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions |
| 06/24/2004 | CA2509662A1 A method for treatment of drug addiction and for screening of pharmaceutical agents therefor |
| 06/24/2004 | CA2509494A1 Method of introducing sirna into adipocytes |
| 06/24/2004 | CA2509374A1 Glycogen synthase kinase-3 inhibitors |
| 06/24/2004 | CA2508912A1 Oral lactoferrin in the treatment of sepsis |
| 06/24/2004 | CA2508847A1 Central nervous system damage |
| 06/24/2004 | CA2508796A1 Topical anti-infective formulations |
| 06/24/2004 | CA2508773A1 Canine rankl and methods for preparing and using the same |
| 06/24/2004 | CA2508769A1 Antibacterial compounds having a (pyrrole carboxamide)-(benzamide)-(imidazole carboxamide) motif |
| 06/24/2004 | CA2508762A1 Methods and compositions for treatment of otitis media |
| 06/24/2004 | CA2508715A1 Materials and methods relating to treatment of injury and disease to the central nervous system |
| 06/24/2004 | CA2508606A1 Pharmacological vitreolysis |
| 06/24/2004 | CA2507980A1 Pharmaceutical compositions preparation of peptides, secreted by the snake venom glands |
| 06/24/2004 | CA2507496A1 Molecular determinants of myeloma bone disease and uses thereof |
| 06/24/2004 | CA2507156A1 Methods of therapy and diagnosis using targeting of cells that express lax |
| 06/24/2004 | CA2506114A1 Cyanomethyl derivatives as cysteine protease inhibitors |
| 06/24/2004 | CA2504357A1 Antisense modulation of mitoneet expression |
| 06/23/2004 | EP1431762A1 Compounds and methods for detection of carcinomas and their precursor lesions |
| 06/23/2004 | EP1431391A2 Rantes mutants and therapeutic applications thereof |
| 06/23/2004 | EP1431311A1 Immunotherapy of B-cell malignancies using anti-CD22 and anti-CD20 antibodies in combination |
| 06/23/2004 | EP1431309A1 Colon specific genes and proteins |
| 06/23/2004 | EP1431308A1 Enzyme phosphorylating ser46 of p53 |
| 06/23/2004 | EP1431307A1 Inactive transcription factor TIF-IA and uses thereof |
| 06/23/2004 | EP1431306A1 A mechanism for hiv-1 entry into host cells and peptides inhibiting this mechanism |
| 06/23/2004 | EP1430904A1 Desensitizers |
| 06/23/2004 | EP1430903A1 Use of proteasome inhibitors for the treatment of viral infections |
| 06/23/2004 | EP1430902A1 Pharmaceutical composition of interferon gamma with molecular diagnostics for the improved treatment of asthma bronchiale |
| 06/23/2004 | EP1430899A1 Graft from submucosal intestinal tissue for repairing neurological tissue |
| 06/23/2004 | EP1430890A1 Thrombus/thrombogenesis inhibitors |
| 06/23/2004 | EP1430304A1 Method and agent for diagnosing and treating chronic inflammatory bowel diseases |
| 06/23/2004 | EP1430302A2 Inhibitors of glycosaminoglycans |
| 06/23/2004 | EP1430157A2 RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS C VIRUS (HCV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 06/23/2004 | EP1430146A2 Novel nucleic acids and polypeptides |
| 06/23/2004 | EP1430144A2 METHODS OF USING 69039, A NOVEL HUMAN Na/Ca EXCHANGER FAMILY MEMBER |
| 06/23/2004 | EP1430140A2 Isoform-selective inhibitors and activators of pde3 cyclic |
| 06/23/2004 | EP1430136A1 Muteins of apolipoprotein d |
| 06/23/2004 | EP1430133A2 A soluble toll-like receptor |
| 06/23/2004 | EP1430132A2 Methods of using 33751, a human potassium channel family member |
| 06/23/2004 | EP1430131A2 Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| 06/23/2004 | EP1430130A2 Nucleic acid-associated proteins |
| 06/23/2004 | EP1430129A2 Asip-related proteins |
| 06/23/2004 | EP1430128A2 Micro-rna molecules |
| 06/23/2004 | EP1430127A1 Polynucleotide fragments of an infectious human endogenous retrovirus |
| 06/23/2004 | EP1430126A1 Dna sequences for human angiogenesis genes |
| 06/23/2004 | EP1430125A2 Sperm-specific cation channel, and uses therefor |
| 06/23/2004 | EP1430114A2 Prolactin induced increase in neural stem cell numbers and therapeutical use thereof |
| 06/23/2004 | EP1430113A2 Effect of growth hormone and igf-1 on neural stem cells and therapeutic application |
| 06/23/2004 | EP1430110A2 Novel antibodies that bind to antigenic polypeptides, nucleic acids and encodingthe antigens, and methods of use. |
| 06/23/2004 | EP1430085A1 Leukocyte inactivation module |
| 06/23/2004 | EP1430084A2 Peptides capable of modulating immune response |
| 06/23/2004 | EP1430080A2 Genetic sequences related to bone diseases in the osteopetrotic grey-lethal (gl) mouse |
| 06/23/2004 | EP1430076A2 Polypeptides derived from inducible hsp70 and pharmaceutical compositions containing the same |
| 06/23/2004 | EP1430075A2 Antibacterial macrocycles |
| 06/23/2004 | EP1430072A2 Antisense modulation of cholesteryl ester transfer protein expression |
| 06/23/2004 | EP1430045A1 Pyrane derivatives as both ace- and nep-inhibitors |
| 06/23/2004 | EP1429845A2 Treatment or prophylaxis of insulin-producing cell graft rejection |
| 06/23/2004 | EP1429817A1 Porous ceramic composite bone grafts |
| 06/23/2004 | EP1429815A1 Mixture for use as a protective dressing |
| 06/23/2004 | EP1429806A2 Extracellular massengers |
| 06/23/2004 | EP1429804A2 Inhibitors of costimulation by ox40 and their use against infectious diseases |
| 06/23/2004 | EP1429802A1 Delivery system for biological component |
| 06/23/2004 | EP1429801A1 Neuropilin as a novel therapeutic target for modulation of immune reponses |
| 06/23/2004 | EP1429800A2 Vaccine and method for treatment of motor neurone diseases |
| 06/23/2004 | EP1429799A2 Kgf polypeptide compositions |
| 06/23/2004 | EP1429798A1 Optimal compositions and methods thereof for treating hcv infections |
| 06/23/2004 | EP1429797A2 Diagnosis and treatment of malignant neoplasms |
| 06/23/2004 | EP1429796A2 Peptide antiangiogenic drugs |
| 06/23/2004 | EP1429778A1 Protopanaxadiol and protopanaxatriol and their use as synergistic anti-cancer agents |
| 06/23/2004 | EP1429763A2 NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER |
| 06/23/2004 | EP1429731A1 Nanoparticulate insulin formulations |
| 06/23/2004 | EP1429723A1 Treating effects of excessive reactive oxygen species |
| 06/23/2004 | EP1429689A1 Rational drug therapy device and methods |
| 06/23/2004 | EP1429650A2 Alternatively spliced circulating tissue factor |